Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1 by Liaozhang Wu (8371008)

“…Mitophagy inhibitor Mdivi-1 reversed the induction of ferroptosis effects of diquat via decreased Fe2+ content and increased Ca2+ level. knockdown of METTL14 reversed the therapeutic effect of Eda on diquat-induced injury. …”

Image 4_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 8_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 10_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Image 2_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”

Table13_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table6_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table4_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table8_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table12_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table3_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xlsx by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table10_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table9_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table1_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”

Table5_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

“…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”